ISC2019:微创手术去除出血性卒中后更多积血可改善患者结局

2019-02-09 国际循环编辑部 国际循环

2019年2月6~8日,芝加哥大学医学与生物科学系神经血管外科主任Issam A. Awad教授在ISC主会场发布的一项最新临床试验MISTIE指出,出血性卒中后通过微创手术从大脑中清除积血量越大,患者功能改善概率越高,临床结局更好。

2019年2月6~8日,芝加哥大学医学与生物科学系神经血管外科主任Issam A. Awad教授在ISC主会场发布的一项最新临床试验MISTIE指出,出血性卒中后通过微创手术从大脑中清除积血量越大,患者功能改善概率越高,临床结局更好。

微创手术联合具有凝块破坏作用的阿替普酶用于脑内出血清除(MISTIE)是立体定向导管吸入和清除脑内大出血的一项最新研究。MISTIE Ⅲ试验是第一次手术试验,评估去除更大量的积血是否具有有利于一年后患者功能结局的可能性,以及与更高的血液清除率相关的因素。

在参加试验的506例脑出血(ICH)病例中,242例ICH患者(平均年龄62岁,男性63%)接受了来自73个中心的110名外科医生的MISTIE Ⅲ外科手术,随访一年。该试验排除出血未稳定的患者和小脑及脑干出血患者。

研究人员发现,在接受MISTIE Ⅲ外科手术的病例中,治疗结束时将血容量减少70%或更多,或者留下15 ml或更少的残余血液,一年之后实现轻度残疾的可能性是其两倍。去除更多的残余血液以避免死亡很必要,但去除血液少于70%或残留血量超过15 ml的患者与使用药物治疗的患者或去除血量较少的患者相比,残疾无显著差异。

研究者指出,具有MISTIE技术经验最丰富的外科医生和中心,在具有某些形状的血肿情况下,其中,严格遵循手术方案的 ICH积血清除更有效。在评估脑出血手术结果时,考虑成功清除多少积血至关重要。除非大部分血栓被清除,只剩非常少量的血液,否则手术的完全益处将无法实现。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-11 vera_1203
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-11 yankaienglish
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-10 Janeinair

    这项技术中国应该没有开展吧?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-10 txqjm

    谢谢了,学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1671368, encodeId=ebd016e136884, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Sep 08 00:36:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309487, encodeId=d2f3130948efb, content=<a href='/topic/show?id=64ee5052ea7' target=_blank style='color:#2F92EE;'>#微创手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50527, encryptionId=64ee5052ea7, topicName=微创手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317052, encodeId=25c3131e05249, content=<a href='/topic/show?id=df8950505a2' target=_blank style='color:#2F92EE;'>#微创#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50505, encryptionId=df8950505a2, topicName=微创)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319563, encodeId=7c2a131956352, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480020, encodeId=3cb314800208c, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587863, encodeId=eddd158e863d9, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Feb 11 14:36:00 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360357, encodeId=2dbb36035ebf, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Feb 11 01:08:37 CST 2019, time=2019-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360340, encodeId=3a7e360340a7, content=这项技术中国应该没有开展吧?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Sun Feb 10 18:17:24 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360294, encodeId=7c1b36029449, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sun Feb 10 06:32:47 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026290, encodeId=0456102629083, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sun Feb 10 02:36:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-10 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Clin Chim Acta:基线C反应蛋白较高与缺血性卒中风险增加相关

背景:有关超敏C-反应蛋白(hs-CRP)和卒中的风险之间的研究结果是相互矛盾的。目标:为确定基线hs-CRP升高的是否是不同类型的卒中的独立危险因素。方法:系统搜索PubMed、EMBASE、Cochrane图书馆、中国知网和万方数据库中2015年1月前发表的前瞻性观察性研究。研究报告超敏c反应蛋白水平和hs-CRP和不同卒中亚型的水平和校正风险评估值。总结果用校正风险比(RR)来表示,及相应的

CHEST:肾功能衰竭患者直接口服抗凝血剂预防大出血和出血性卒中的风险

直接口服抗凝血剂(DOACs)被用作传统的抗血栓治疗的替代方案。然而,DOACs的在肾功能衰竭患者(RF)中的安全性尚未确定。研究人员进行了一项系统性研究,评估DOACs与维生素K拮抗剂(VKAs)相比治疗RF患者的安全性,以肌酐清除率(eCrCL)<50mL/min和eCrCL为50至80mL/min的患者分类进行评估。研究人员检索了MEDLINE,EMBASE,Cochrane,以及临床

PLoS One:中国人群出血性卒中和缺血性卒中的时间趋势(2001-2012)

背景:脑卒中的临床流行病学已在高加索人群中得到了广泛的研究,但随着时间的改变,缺血/出血性卒中的比例,变化是不太清楚,尤其是中国人群。目的:研究者的目的是在大型中国人口队列中,研究与年龄相关的缺血性和出血性卒中的决定因素及时间趋势。方法:使用2001到2012间中国西南部医疗保险数据库,年龄校正的缺血性和出血性卒中发病率的变化趋势,及与年龄相关的危险因素。结果: 无卒中史的425901(52.4%

Neurology:确切数据告诉你肥胖与卒中之间的关系

目的该研究的目的在于通过收集全球数据比较BMI与缺血性卒中和出血性卒中风险之间的关联。方法研究人员在1996-2001年招募了130万名无卒中病史的英国女性(平均年龄为57岁),并对她们进行了持续随访,收集她们的住院信息和死亡信息。之后使用Cox回归分析来评估BMI与参与者患缺血性和出血性卒中(脑出血或蛛网膜下腔出血)风险之间的关系。此外,研究人员收集所有相关前瞻性研究进行荟萃分析。结果平均随访时

Stroke:神经纤维瘤病1型患者发生脑血管疾病的风险增加

背景和目的:尽管神经纤维瘤病1型(NF1)可能与不明原因的血管病变相关,但是这人群众发生卒中的几率尚不清楚。方法:应用美国1998年到2009年全国住院样本,研究者进行了一项病例对照研究,将NF1患者与未诊断为NF1的受试者配对。然后,研究者比较2组受试者卒中的发生。研究者应用多变量logistic回归校正已知或可疑的混杂因素。结果:NF1患者发生卒中的年纪较小,成人患者中卒中危险因素较低。NF1

Stroke:青年先天性心脏病患者出血性卒中的长期风险!

由此可见,CHD儿童和年轻人发生出血性卒中的相对风险几乎是一般人群的8倍,尽管绝对风险较低。重症非圆锥动脉干缺陷或主动脉缩窄患者发生ICH和SAH的风险最高。